Table 3.

Variables associated with mortality

(N=60 cases)	Alive at discharge (N=34; 57%)	Deceased (N=26; 43%)	p-value (univ.)	p-value (multiv.)	OR (multiv.)
Duration of ketamine; days; median (range)	4 (0–24)	4 (0–27)	NS	-	-
Dose of ketamine; mg/kg/h; median (range)	1.7 (0.05–10)	3.6 (0–10)	NS	-	-
Response to ketamine (N=19); N (row %)	16 (84%)	3 (16%)	0.0014	0.001	0.007–0.3
Age; years; median (range)	26 (7mo–85)	51 (19–76)	0.0025	<0.001	1.02–1.1/year
Etiology			0.0127	NS	-
Unknown (N=34); N (row %)	18 (53%)	16 (47%)
Anoxic (N=7); N (row %)	2 (29%)	5 (71%)
Acute non anoxic (N=13); N (row %)	9 (69%)	4 (31%)
Remote (N=6); N (row %)	5 (83%)	1 (17%)
Status classification			NS	-	-
Generalized convulsive (N=14); N (row %)	8 (56%)	6 (44%)
Generalized nonconvulsive (N=3); (row %)	1 (33%)	2 (67%)
Focal convulsive (N=4); N (row %)	2 (50%)	2 (50%)
Focal nonconvulsive (N=38); N (row %)	25 (66%)	13 (33%)
Status epilepticus of infantile spasms; N (row %)	1 (100%)	0 (0%)
Any adverse event (N=18); N (row %)	8 (44)	10 (66%)	NS	-	-
Concurrent anesthetic drugs*; median (range)	2 (0–3)	2 (1–3)	NS	-	-

Abbreviations: univ. = univariate analysis; multiv. = multivariate analysis;;

^*anesthetic drugs include pentobarbital, thiopental, midazolam and propofol.